Theravance Biopharma Inc (NASDAQ:TBPH) Short Interest Down 7.0% in September

Share on StockTwits

Theravance Biopharma Inc (NASDAQ:TBPH) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 3,300,000 shares, a decline of 7.0% from the August 30th total of 3,550,000 shares. Based on an average daily trading volume, of 246,400 shares, the days-to-cover ratio is presently 13.4 days. Approximately 7.7% of the shares of the stock are sold short.

A number of research firms have weighed in on TBPH. BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Friday, October 11th. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Theravance Biopharma in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $44.25.

Shares of NASDAQ TBPH opened at $17.17 on Friday. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $30.34. The firm has a market capitalization of $974.16 million, a price-to-earnings ratio of -4.30 and a beta of 1.64. The business has a 50-day moving average of $20.55 and a 200-day moving average of $20.02.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.50. The business had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $13.92 million. As a group, analysts anticipate that Theravance Biopharma will post -4.34 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Simplex Trading LLC grew its holdings in shares of Theravance Biopharma by 30.1% during the third quarter. Simplex Trading LLC now owns 5,043 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,167 shares in the last quarter. Opti Capital Management LP purchased a new position in shares of Theravance Biopharma during the second quarter worth about $1,303,000. Northern Trust Corp grew its holdings in shares of Theravance Biopharma by 0.6% during the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock worth $9,041,000 after purchasing an additional 3,547 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Theravance Biopharma by 64.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 7,500 shares in the last quarter. Finally, CWM Advisors LLC purchased a new position in shares of Theravance Biopharma during the second quarter worth about $167,000. 84.16% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Article: What is Compound Interest?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.